Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.45 (market cap $8.04B), while Materials Select Sector SPDR Fund trades at $50.73. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | XLB | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | — |
52-Week High | $339.75 | $53.62 |
52-Week Low | $241.71 | $42.23 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
XLB trades at $50.58, down 0.61% with bearish technical signals from moving averages. The materials ETF faces mixed sentiment as recent sector gains appear priced in, though infrastructure trends provide underlying support. Key support sits at $50 with resistance at $51. Recent analysis suggests limited near-term upside despite sector tailwinds from manufacturing and energy security themes.
Outlook remains cautious with technical indicators favoring bearish momentum. The materials sector benefits from infrastructure spending but faces geopolitical sensitivity and valuation concerns after recent gains. Investment opportunity exists for long-term exposure to industrial materials, though current entry timing appears suboptimal given technical weakness and priced-in cyclical recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
